ArticlePloS one2024
Citrate-modified bacterial cellulose as a potential scaffolding material for bone tissue regeneration.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial cellulose (BC) is a novel biocompatible polymeric biomaterial with a wide range of biomedical uses, like tissue engineering (TE) scaffolds, wound dressings, and drug delivery. Although BC lacks good cell adhesion due to limited functionality, its tunable surface chemistry still holds promise. Here, hydroxyapatite (HA) was incorporated into a citrate-modified BC (MBC) using the biomimetic synthesis in simulated body fluid (SBF). Fourier transform infrared (FTIR) spectroscopy, X-ray diffraction (XRD), field emission scanning electron microscopy (FE-SEM), thermal gravimetric analysis (TGA), and compressive modulus were used to characterize the biomineralized MBC (BMBC) samples. Using 3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium (MTS), trypan blue dye exclusion (TBDE), and cell attachment assays on osteoblast cells, the developed BMBC have shown good cell viability, proliferation, and attachment after 3, 5, and 7 days of culture and therefore suggested as potential bone tissue regeneration scaffolding material.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.